Back to Directory

Published

Headquarters
Edinburgh 🏴󠁧󠁢󠁳󠁣󠁴󠁿
Employee Count
10
Year Founded
2020
Amount raised
$4.7M
Business model
Currently B2B with plans to roll out a consumer offering
Early traction
Adopted by 1 in 4 U.S. sports teams, 14k sessions logged a month, 36% of hardware used daily, endorsed by major athletes including Dak Prescott and Justin Rose

Setting the Scene

  • Chronic musculoskeletal pain (MSK) affects more than 50% of the adult population, inhibiting daily activities and quality of life.

  • Improving muscle strength is a modifiable factor for reducing MSK pain, however, most solutions fall short.

    • Strength training isn’t hyper-targeted.

    • Recovery products fail to provide insights.

    • Physical therapy is ongoing, costly, and inconvenient.

  • This week’s company provides technology to strengthen muscle groups, accelerate recovery, and relieve MSK.

In a Sentence

Suji develops devices and a companion platform that utilizes targeted compression training to measure and improve muscle strength as well as accelerate recovery.

  • Compression Training: A portable device is worn during exercise and controlled via smartphone, isolating muscles during low-intensity workouts to strengthen them.

  • Platform: The app tracks and guides workouts to accelerate recovery, endurance, and strength training.

Bulleted Version

Think of Suji as a blend between the techniques of a physical therapist and WHOOP, utilizing a wearable device to track and improve muscle strength with targeted compression therapy.

Due Diligence

What We Like

  • Market Opportunity: With roughly 50% of Americans suffering from MSK pain, Suji’s unique product capitalizes on sports medicine, consumer health, and healthy aging markets.

  • Early Insights: Early studies have shown that Suji’s ability to quantify muscle states has led the average user to improve muscle strength by up to 31% in just six weeks.

  • Defensible Moat: With multi-patent pending hardware on this new kind of therapy and an increasing dataset of public muscle state, Suji creates barriers to entry among competitors.

Potential Risks

  • Liability: As Suji’s technology involves physical health interventions, there is the potential liability of users experiencing adverse effects or injuries, necessitating robust safety protocols and insurance.

  • Data and Security: Handling and storing vast amounts of user data could pose significant data privacy and security risks, requiring stringent measures to protect sensitive information from breaches and misuse.

  • Regulatory Compliance: Navigating the complex landscape of health regulations across different markets can be challenging, potentially impacting Suji's ability to operate smoothly and increasing the risk of non-compliance penalties.

Founder Profile

AB
Alex Birks, CEO
Former national boxing champion with a background in robotic engineering.
CM
Connor McGuile, CTO
Previously an algorithms engineer at Thales with an MS in AI.

WhySuji

Suji’s patented, cutting-edge technology has gained traction by working with top players and teams, showing the company’s strength as it continues to scale.

*Nothing in this content constitutes investment or legal advice. Conduct independent diligence and consult professional advisers before making investment decisions.*

Explore other features

SF

2026-10-28

Talp

Talp is an AI-powered customer simulation platform that helps businesses predict how customers might respond to pricing changes, product launches, and marketing campaigns before making those decisions.

Business model

Annual B2B contracts

Read More: Talp

NYC

2026-10-13

Snag

Snag is a socially-native marketplace for apartments that helps renters discover, verify, and pay for flexible rentals.

Business model

Fees taken on rent processed through the marketplace

Read More: Snag

NYC

2026-09-29

Ophelia

Ophelia is the discovery, authentication, and transaction layer that lets AI agents securely act on your behalf without relying on web browsers.

Business model

Usage-based API pricing tied to confirmed outcomes

Read More: Ophelia